Silverarc Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Silverarc Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,000	Closed	-$2.08M	–	78
2025 Q3	$2.08M	Buy	+50,000	New	+$1.6M	0.28%	61
2024 Q2	–	Sell	-127,835	Closed	-$5.98M	–	75
2024 Q1	$5.98M	Buy	+127,835	New	+$5M	1.66%	23
2023 Q4	–	Sell	-220,000	Closed	-$6.54M	–	76
2023 Q3	$6.54M	Buy	+220,000	New	+$4.53M	1.98%	17
2023 Q1	–	Sell	-152,747	Closed	-$2.8M	–	85
2022 Q4	$2.8M	Buy	152,747 +3,720	+2%	+$65.6K	0.8%	44
2022 Q3	$2.93M	Buy	149,027 +9,488	+7%	+$193K	0.99%	33
2022 Q2	$2.6M	Buy	139,539 +25,535	+22%	+$510K	0.8%	34
2022 Q1	$2.5M	Buy	114,004 +2,144	+2%	+$43.4K	1.04%	25
2021 Q4	$3.18M	Buy	111,860 +62,478	+127%	+$1.54M	1.29%	25
2021 Q3	$1.04M	Buy	+49,382	New	+$1.03M	0.59%	56

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Silverarc Capital Management's CRNX Position: Q4 2025 in Review

Silverarc Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 50,000 shares — an estimated $2.08M sold.

Silverarc Capital Management first reported a position in CRNX in Q3 2021 and held it in 9 quarters. The position peaked at $6.54M in Q3 2023. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

Silverarc Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Silverarc Capital Management sold 50,000 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $2.08M.
Silverarc Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Silverarc Capital Management's Crinetics Pharmaceuticals position peaked at $6.54M in Q3 2023.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.